Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance

Type 2 diabetes mellitus (T2DM) increases morbimortality in humans via enhanced susceptibility to cardiovascular disease (CVD). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are drugs designed for T2DM treatment to diminish hyperglycaemia by reducing up to 90% of renal tube glucose reabsorptio...

Descripción completa

Detalles Bibliográficos
Autores principales: Taberner-Cortés, Alida, Vinué, Ángela, Herrero-Cervera, Andrea, Aguilar-Ballester, María, Real, José Tomás, Burks, Deborah Jane, Martínez-Hervás, Sergio, González-Navarro, Herminia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730942/
https://www.ncbi.nlm.nih.gov/pubmed/33287201
http://dx.doi.org/10.3390/ijms21239216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730942/
https://www.ncbi.nlm.nih.gov/pubmed/33287201
http://dx.doi.org/10.3390/ijms21239216

Ejemplares similares